Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Professionals Reference (MPR)
Findings from both trials showed treatment with elinzanetant led to a statistically significant reduction (≥2 hot flashes over 24 hours) in the frequency of moderate to severe VMS compared with placebo at both 4 and 12 weeks across OASIS 1 and 2 studies.
Obstetrics & Gynecology November 11th 2025
Conexiant
Assessment highlights a disconnect between the pharmacokinetic expectations of the three-month estradiol vaginal ring and the lived experience of some patients using it, which in some cases greatly impacts the quality of life.
Endocrinology, Diabetes, Metabolism October 24th 2025
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS